Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1CNS 1

Conditions

Leukemia, Myeloid, Acute 6Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid 2Leukemia 2Primary Myelofibrosis 1Multiple Myeloma 1Leukemia, Monocytic, Acute 1Immunoblastic Lymphadenopathy 1Hematologic Neoplasms 1Glioma 1Clonal Cytopenia of Undetermined Significance 1Chondrosarcoma 1Cholangiocarcinoma 1

Interventions

Cyclophosphamide 20fludarabine phosphate 19Peripheral Blood Stem Cell Transplantation 18Whole-Body Irradiation 15Cyclosporine 12Mycophenolic Acid 11Etoposide 9Busulfan 9Prednisone 8Vincristine 7Tacrolimus 7Filgrastim 7Carboplatin 7Bortezomib 7Antilymphocyte Serum 7Methotrexate 6Everolimus 6Doxorubicin 6Vorinostat 5Rituximab 5Gemcitabine 5Therapeutics 4Radiotherapy 4Panobinostat 4Paclitaxel 4Melphalan 4Lenalidomide 4Gene Expression Profiling 4Methylprednisolone 3MLN 8237 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Immunoblastic Lymphadenopathy × enasidenib × Clear all
NCT02273739 2021-02-23

Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation

Celgene

Phase 1/2 Completed
21 enrolled 33 charts
CNSGastrointestinalSarcoma

Chondrosarcoma, Glioma, Immunoblastic Lymphadenopathy, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡